Enzyme Replacement Therapy Market Report 2024: Strategies And Recent Developments | Biomarin Pharmaceutical Inc., Leadiant Biosciences Inc., Pfizer Inc., Sanofi S.A., AbbVie Inc., Genzyme Corporation, Johnson & Johnson Services Inc.

The Business Research Company has updated its global market reports, featuring the latest data for 2024 and projections up to 2296

The Business Research Company offers in-depth market insights through Enzyme Replacement Therapy Global Market Report 2024, providing businesses with a competitive advantage by thoroughly analyzing the market structure, including estimates for numerous segments and sub-segments.

Market Size And Growth Forecast:
The enzyme replacement therapy market size has grown strongly in recent years. It will grow from $10.85 billion in 2023 to $11.72 billion in 2024 at a compound annual growth rate (CAGR) of 8.0%. The growth in the historic period can be attributed to growing early therapeutic discoveries, pioneering treatment approvals, expanded disease understanding, clinical success stories, regulatory support and incentives.

The enzyme replacement therapy market size is expected to see strong growth in the next few years. It will grow to $16.21 billion in 2028 at a compound annual growth rate (CAGR) of 8.5%. The growth in the forecast period can be attributed to increasing patient access to healthcare, tailored therapies and personalized medicine, regulatory landscape changes, growing patient population awareness. Major trends in the forecast period include digital health integration, focus on patient-centric solutions, emerging biomarker research, precision medicine approach.

Get Free Sample Of This Report-
https://www.thebusinessresearchcompany.com/sample.aspx?id=10512&type=smp

Market Segmentation:
The enzyme replacement therapy market covered in this report is segmented -

1) By Enzyme Type: Agalsidase Alfa, Agalsidase Beta, Galsulfase, Other Enzyme Types
2) By Route Of Administration: Oral, Parenteral
3) By Application: Gaucher Disease, Pompe Disease, Fabry Disease, Other Applications
4) By End-Users: Hospitals, Infusion Centers, Other End-Users

Major Driver - Enzyme Replacement Therapy Market Set To Surge Due To Escalating Prevalence Of Chronic And Inherited Disorders
The rising prevalence of rare, chronic, and inherited disorders is expected to propel the growth of the enzyme replacement therapy market going forward. Chronic disease refers to a form of illness that lasts for three months or more and can deteriorate with time. Chronic diseases are more common in elderly people and typically can be controlled but not eradicated. For instance, in January 2023, according to a report issued by the US-based National Library of Medicine, which is operated by the federal government, the number of people in the USA aged 50 and older who have at least one chronic condition will increase by 99.5%, from 71.522 million in 2020 to 142.66 million by 2050. Therefore, the rising prevalence of rare, chronic, and inherited disorders will drive the growth of the enzyme replacement therapy market going forward.

Competitive Landscape:
Major companies operating in the enzyme replacement therapy market report are Biomarin Pharmaceutical Inc., Leadiant Biosciences Inc., Pfizer Inc., Sanofi S.A., AbbVie Inc., Genzyme Corporation, Johnson & Johnson Services Inc., Alexion Pharmaceuticals Inc., Shire plc, Recordati Rare Diseases Inc., Actelion Pharmaceuticals Ltd., Sangamo Therapeutics Inc., JCR Pharmaceuticals Co. Ltd., Horizon Pharma Public Limited Company, Protalix Biotherapeutics Ltd., Amicus Therapeutics Inc., AstraZeneca plc, Zoetis Inc., Novartis AG, Roche Holding AG, GlaxoSmithKline plc, Merck & Co. Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, Sangamo Therapeutics Inc, Retrophin Inc., Abeona Therapeutics Inc., Orchard Therapeutics plc, Ultragenyx Pharmaceutical Inc, Catalyst Biosciences

Get Access To The Full Market Report -
https://www.thebusinessresearchcompany.com/report/enzyme-replacement-therapy-global-market-report

Top Trend - Fda Approves Lamzede Groundbreaking Enzyme Replacement Therapy For Alpha-Mannosidosis
Product approvals have emerged as the key trend gaining popularity in the enzyme replacement therapy market. Several enzyme replacement therapy medications introduced by large players are getting approvals in the market. For instance, in February 2023, the Food and Drug Administration, a US-based federal agency of the Department of Health, approved Lamzede (velmanase alfa), the first enzyme replacement therapy approved in the United States for the treatment of non-central neurological indications of alpha-mannosidosis, a rare genetic disorder characterized by an absence of the alpha-mannosidase enzyme in the body. Lamzede helps patients regain normal cellular function by acting similarly to the alpha-mannosidase enzyme in their bodies, restoring healthy cellular functioning in patients. Lamzede is administered to patients once a week as a 10mg injection.

The Table Of Content For The Market Report Include:
1. Executive Summary
2. Enzyme Replacement Therapy Market Characteristics
3. Enzyme Replacement Therapy Market Trends And Strategies
4. Enzyme Replacement Therapy Market - Macro Economic Scenario
5. Enzyme Replacement Therapy Market Size And Growth
…..
27. Enzyme Replacement Therapy Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a market intelligence firm that pioneers in company, market, and consumer research. Located globally, TBRC's consultants specialize in various industries including manufacturing, healthcare, financial services, chemicals, and technology. The firm has offices located in the UK, the US, and India, along with a network of proficient researchers in 28 countries.

This release was published on openPR.